CaMKII-dependent non-canonical RIG-I pathway promotes influenza virus propagation in the acute-phase of infection
mBio · 2025
DOI: 10.1128/mbio.00087-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Shinichiro Hama und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Life Sciences, Graduate School of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan. Hauptthemen laut MEDLINE: Calcium-Calmodulin-Dependent Protein Kinase Type 2, DEAD Box Protein 58, Orthomyxoviridae Infections, Influenza A virus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), Takeda Science Foundation (TSF), Japan Agency for Medical Research and Development (AMED).
Abstract (Originalsprache)
Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) is one of hundreds of host-cell factors involved in the propagation of type A influenza virus (IAV), although its mechanism of action is unknown. Here, we identified CaMKII inhibitory peptide M3 by targeting its kinase domain using affinity-based screening of a tailored random peptide library. M3 inhibited IAV cytopathicity and propagation in cells by specifically inhibiting the acute-phase activation of retinoic acid-inducible gene I (RIG-I), which is uniquely regulated by CaMKII. Downstream of the RIG-I pathway activated TBK1 and then IRF3, which induced small but sufficient amounts of transcripts of the genes for IFN α/β to provide the capped 5’-ends that were used preferentially as primers to synthesize viral mRNAs by the cap-snatching mechanism. Importantly, knockout of RIG-I in cells almost completely inhibited the expression of IFN mRNAs and subsequent viral NP mRNA early in infection (up to 6 h after infection), which then protected cells from cytopathicity 24 h after infection. Thus, CaMKII-dependent acute-phase activation of RIG-I promoted IAV propagation, whereas the canonical RIG-I pathway stimulated antiviral activity by inducing large amounts of mRNA for IFNs and then for antiviral proteins later in infection. Co-administration of M3 with IAV infection rescued mice from the lethality and greatly reduced proinflammatory cytokine mRNA expression in the lung, indicating that M3 is highly effective against IAV in vivo . Thus, regulation of the CaMKII-dependent non-canonical RIG-I pathway may provide a novel host-factor-directed antiviral therapy. IMPORTANCE The recent emergence of IAV strains resistant to commonly used therapeutic agents that target viral proteins has exacerbated the need for innovative strategies. Here, we originally identified CaMKII-inhibitory peptide M3, which efficiently inhibits IAV-lethality in vitro and in vivo . M3 specifically inhibited the acute-phase activation of RIG-I, which is a novel pathway to promote IAV propagation. Thus, this pathway acts in an opposite manner compared with the canonical RIG-I pathway, which plays essential roles in antiviral innate immune response later in infection. The CaMKII-dependent non-canonical RIG-I pathway can be a promising and novel drug target for the treatment of infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Life Sciences, Graduate School of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan.
- Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
- Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Hokkaido, Japan.
- Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, Japan.
- Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Hokkaido, Japan.
- Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Hokkaido, Japan.
ORCID-Profile: Miho Watanabe-Takahashi, Kiyotaka Nishikawa
Förderung
- MEXT | Japan Society for the Promotion of Science (JSPS)
- Takeda Science Foundation (TSF)
- Japan Agency for Medical Research and Development (AMED)
- MEXT | Japan Science and Technology Agency (JST)
Zitieren
APA
Hama, S., Watanabe-Takahashi, M., Nishimura, H., Omi, J., Tamada, M., Saitoh, T., Maenaka, K., Okuda, Y., Ikegami, A., Kitagawa, A., Furuta, K., Izumi, K., Shimizu, E., Nishizono, T., Fujiwara, M., Miyasaka, T., Takamori, S., Takayanagi, H., Nishikawa, K., …, & Nishikawa, K. (2025). CaMKII-dependent non-canonical RIG-I pathway promotes influenza virus propagation in the acute-phase of infection. mBio. https://doi.org/10.1128/mbio.00087-24
Vancouver
Hama S, Watanabe-Takahashi M, Nishimura H, Omi J, Tamada M, Saitoh T, et al. CaMKII-dependent non-canonical RIG-I pathway promotes influenza virus propagation in the acute-phase of infection. mBio. 2025. doi:10.1128/mbio.00087-24
BibTeX
@article{Hama2025,
author = {Hama, Shinichiro and Watanabe-Takahashi, Miho and Nishimura, Hiroki and Omi, Jumpei and Tamada, Masakazu and Saitoh, Takashi and Maenaka, Katsumi and Okuda, Yuta and Ikegami, Aoi and Kitagawa, Asami and Furuta, Koudai and Izumi, Kana and Shimizu, Eiko and Nishizono, Takashi and Fujiwara, Makoto and Miyasaka, Tomohiro and Takamori, Shigeo and Takayanagi, Hiroshi and Nishikawa, Keizo and Kobayashi, Toshihiko and Toyama-Sorimachi, Noriko and Yamashita, Makoto and Senda, Toshiya and Hirokawa, Takatsugu and Bito, Haruhiko and Nishikawa, Kiyotaka},
title = {CaMKII-dependent non-canonical RIG-I pathway promotes influenza virus propagation in the acute-phase of infection},
journal = {mBio},
year = {2025},
doi = {10.1128/mbio.00087-24}
}
EUVIMED